Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Subcutaneous Efgartigimod Expands Payer Potential For Argenx’s Drug

Offers gMG Patients Freedom From I.V. Treatment

Executive Summary

With positive Phase III data for the injectable version of its myasthenia gravis therapy, the company expects most patients to use it over intravenous Vyvgart, opening more avenues for reimbursement.

You may also be interested in...

Takeda Gets FDA Nod For HyQvia In CIDP

The drug could become competitive with Argenx’s Vyvgart Hytrulo, but the market opportunity for the rare disease remains unclear due to continued diagnostic challenges.

Argenx’s I.V. Vyvgart May See Continued Role In ITP, Despite SubQ Version Coming

The company presented Phase III data for the I.V. formulation at ASH showing a high response rate in pretreated patients, a difficult-to-treat population. It also has a subcutaneous version in Phase III.

Finance Watch: Public Markets Open Back Up For Biopharma Offerings

Public Company Edition: An IPO and three big follow-on offerings hit the market but other public companies revealed plans to cut costs or reprioritize their R&D pipelines, signaling that uncertainty remains. 

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts